

Thursday, 14 November 2024
Nurses' track | Aduana room

13:00 – 14:45 **Session I: CAR-T: What, Why & When**
Chairs: *Ida Bremer Ophorst (NL) & Sophie van Lancker (BE)*

This session will give a general overview of CAR-T treatment in adult and paediatric care. What is CAR-T, what is the indication, what licensed products are used, which differences are there in sequence of CAR-T treatment.

13:00 – 13:15	Welcome from the organizers	Ida Bremer Ophorst (NL) Sophie van Lancker (BE) <i>To be decided</i>
13:15 – 13:35	CAR-T in adult and paediatric care	<i>To be decided</i>
13:35 – 13:55	Apheresis: cell collection for CAR-T treatment in adult and paediatric patient	<i>To be decided</i>
13:55 – 14:10	Paediatric case presentation on nursing perspectives about neurotoxicity's and CRS	<i>To be decided</i>
14:10 – 14:25	Adult case presentation on nursing perspectives about neurotoxicity's and CRS	Ruth Clout (UK)
14:25 – 14:45	ICU perspective	<i>To be decided</i>

14:45 – 15:15 **Coffee Break**

15:15 – 16:45 **Session II: CAR-T, the real Life experience**
Chairs: *Marjola Gjergji (IT) & Daphna Hutt (IL)*

This session will give a more in depth view of what kind of information do we give, how do nurses give and manage information, what tools do they use, what difference are there between adult and paediatric information and communication. What is patients or parents overall experience with CAR-T care.

15:15 – 15:35	The Role of bridging therapy in CAR-T setting	Daphna Hutt (IL)
15:35 – 15:55	Information and communication	Ida Bremer Ophorst (NL) Sophie van Lancker (BE)
15:55 – 16:15	Psycho-social care: The need of the patient and family?	<i>To be decided</i>
16:15 – 16:25	Patient and parent experience	<i>To be decided</i>
16:25 – 16:45	Q&A	

17:30 – 19:00 **Paediatric Diseases Working Party Scientific Business Meeting**
Exclusive meeting for members of the working party.

17:30 – 19:00 **Transplant Complications Working Party Scientific Business Meeting**
Open to all attendees.

Friday, 15 November 2024
Physicians' track | Caleta room

09:00 – 09:10 **Welcome from the organizers**
Chairs: *Krzysztof Kałwak (PL) & Alberto Mussetti (SP)*

09:10 – 10:55 **Session I: Patient journey through CAR-T therapies: panel discussion**
Chair: *Katharina Kleinschmidt (DE) & Ivan Moiseev (RU)*
Presenters: *Valentín Ortiz-Maldonado (SP) & Giovanna Lucchini (IT)*

The session will cover the risk factors for failed CAR-T production, bridging therapies, risk factors for immune complications, risk factors for non-immune complications, aspects of doctor-patient interaction when consulting a patient, options for choosing a particular product in different countries, and aspects of follow-up.

10:55 – 11:25 **Coffee Break**

11:25 – 13:00 **Session II: Supportive care and monitoring**
Chair: *Krzysztof Kałwak (PL) & Giovanna Lucchini (IT)*

11:25 – 12:25 **Prophylaxis of cytokine release syndrome: pro and contra**
Presenters: *Jacopo Mariotti (IT), Susana Rives (SP), Krzysztof Kałwak (PL) & Giovanna Lucchini (IT)*

This part of the session will cover the existing body of evidence on using prophylaxis in CAR-T recipients and the selection of patients for such prophylaxis. The spectrum of potential target therapies for prophylaxis will be covered.

12:25 – 13:10 **Supportive care and monitoring: panel discussion**
Presenters: *Victor Noriega (SP), Grzegorz Basak (PL)*

In this part of the session, the presenters will describe the existing recommendations on supporting care and evaluation of symptoms at various stages after CAR-T therapies. The necessary minimum of laboratory and instrumental workouts will be described.

13:10 – 14:10 **Lunch Break**

14:10 – 15:50 **Session III: Cytokine release syndrome after CAR-T therapies**
Chair: *Alberto Mussetti (SP) & Giovanna Lucchini (IT)*

The session is intended to teach the spectrum of clinical manifestations of CRS, the necessary laboratory and instrumental confirmatory studies, potential histological findings, and differences in presentation in the pediatric and adult populations. The treatment part will cover the optimal timing for initiation of therapy, first and subsequent lines of therapy, and evaluation of response.

14:10 – 14:40 A spectrum of clinical presentations and treatment in pediatric patients
14:40 – 15:10 A spectrum of clinical presentations and treatment in adult and elderly patients Olaf Penack (DE)
15:10 – 15:30 CRS case presentation from abstract and discussion
15:30 – 15:50 CRS case presentation from abstract and discussion

15:50 – 16:20 **Coffee Break**

16:20 – 17:05 **Industry Symposium**

17:05 – 18:35 **Session IV: Neurologic complications of CAR-T therapies**
Chairs: *Roser Velasco (SP) & Jochen Büchner (NO)*

The session focuses on tools to monitor for ICANS and other manifestations of neurotoxicity, and the utility of imaging methods. Treatment overview will include corticosteroids, anti-cytokine, and anticonvulsant therapies. After the session, the attendees will be able to implement monitoring and early intervention protocols in their hospitals.

17:05 – 17:35	Emerging strategies for managing ICANS	Christian Schultze-Florey (DE)
17:35 – 17:55	non-ICANS neurological complications	
17:55 – 18:15	Managing patients with central nervous system involvement	
18:15 – 18:35	Fludarabine-related neurotoxicity: truth or myth?	Roser Velasco (SP)

Friday, 15 November 2024
Nurses' track | Aduana room

09:30 – 11:00 **Session III: The changing face of CAR T therapy and developments (part I)**
Chairs:

This session intends to reflect on the care of CAR-T which is changing. Presenters will zoom in on developments and new technologies. What does this mean for the patient and for the or the care givers?

09:30 – 09:50	Ambulatory care (adult care)
09:50 – 10:10	The place of AI in CAR-T
10:10 – 10:40	Round table discussion: ethical issues, self-care, boundaries in healthcare, and advanced care planning
10:40 – 11:00	Summary moment of all round table groups

11:00 – 11:25 **Coffee Break**

Physicians' track | Caleta room

11:25 – 13:00 **Session II: Supportive care and monitoring**
Chair: *Krzysztof Kałwak (PL) & Giovanna Lucchini (IT)*

11:25 – 12:25 **Prophylaxis of cytokine release syndrome: pro and contra**
Presenters: *Jacopo Mariotti (IT), Susana Rives (SP), Krzysztof Kałwak (PL) & Giovanna Lucchini (IT)*

This part of the session will cover the existing body of evidence on using prophylaxis in CAR-T recipients and the selection of patients for such prophylaxis. The spectrum of potential target therapies for prophylaxis will be covered.

12:25 – 13:10 **Supportive care and monitoring: panel discussion**
Presenters: *Victor Noriega (SP), Grzegorz Basak (PL)*

In this part of the session, the presenters will describe the existing recommendations on supporting care and evaluation of symptoms at various stages after CAR-T therapies. The necessary minimum of laboratory and instrumental workouts will be described.

13:00 – 14:10 **Lunch Break**

Nurses' track | Aduana room

14:10 – 15:50 **Session III: The changing face of CAR T therapy and developments (part II)**

Chairs:

This session intends to reflect on the care of CAR-T which is changing. In this session the presenters will zoom in on developments and new technologies and gives a change to work together to solve CAR-T problems.

14:10 - 14:30	The next step: CAR-T in solid tumours
14:30 - 14:45	Best Paediatric Abstract Grant
14:45 - 15:00	Best Adult Abstract Grant
15:00 - 15:30	Escape Room: Get interactive in CAR-T care
15:30 - 16:00	Summary and farewell

Saturday, 16 November 2024 Physicians' track | Caleta room

09:00 – 10:00 **Session V: Infectious complications after CAR-T therapy**

Chairs: *Isabel Ruiz-Camps (SP) & Rafael de la Cámara (SP)*

This session will provide an overview of recommendations on prophylaxis, current clinical practice, and recommendations on empirical antibacterial and antifungal therapies. The session will also cover difficulties of identifying patients with infections after anti-cytokine therapies, and practical recommendations on antimicrobial therapy in difficult diagnostic situations.

09:00 – 09:20	Current recommendations on prophylaxis of infections after CAR-T therapies	Isabel Ruiz-Camps (SP)
09:20 – 09:40	Differential diagnosis of sepsis and CRS, principles of empirical antimicrobial therapy after CAR-T therapies	Martina Pennisi (IT)
09:40 – 10:00	Case presentation from abstracts and discussion	

10:00 – 10:45 **Industry Symposium**

10:45 – 11:15 **Coffee Break**

11:15 – 13:15 **Session VI: Rare CAR-T complications**

Chair: *Charlotte Graham (UK)*

The session will discuss rare cases of complications after CAR-T therapies, like HLH/MAS, late cytopenia, graft-versus-host disease, pseudo progression and TA-TMA, as well as approaches to their treatment.

11:15 – 11:35	Hemophagocytic Lymphohistiocytosis/Macrophage Activation Syndrome (HLH/MAS) after CAR-T: differential diagnosis from "common" CRS	Giovanna Lucchini (IT)
11:35 – 11:55	Cytopenia after CAR-T: clinical presentation and treatment	
11:55 – 12:15	TA-TMA after CAR-T therapies	Guillaume Dachy (BE)
12:15 – 12:35	Late complications after CAR-T therapies	Charlotte Graham (UK)
12:35 – 13:15	"Never give up until you really have to" case presentation and discussion	Jowita Frączkiewicz (PL)

13:15 – 13:30 **Summary and Farewell**